Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Chemotherapy in Advanced Biliary Tract Cancers
NCT05771480Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 8
01
Overview
A Phase 3 trial of durvalumab in biliary tract cancer (BTC), sponsored by AstraZeneca. Started Aug 2023; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05771480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05771480.